BMI View: A number of developments within the European hepatitis C market indicate that the drug pricing battle seen in the US is extending to Europe. European payers have already secured substantial discounts for existing HCV drugs, yet current cost-containment trends in Europe mean that competitive pricing leading to further discounts is welcomed by European payers.
Table of Contents
- US HCV Drug Pricing Battle To Extend To Europe Antibacterials
- Agreements
- Roche/Meiji/Fedora Enter Collaboration For Development Of OP0595
- Valneva To Acquire Dukoral Vaccine From Crucell
- SinSa Signs Deal For Technology Platform To Prevent Antibiotic Resistance
- R&D
- Aradigm Granted Key Composition Of Matter Patents For Pulmaquin In Europe/Australia
- Galapagos Secures IWT Grant For Antibiotic Research Antifungals
- Product Updates
- FDA Advisory Committee Recommends Cresemba Approval For Invasive Aspergillosis/Mucormycosis
- R&D
- Scynexis' SCY-078 Oral Formulation Gains FDA Fast Track Designation Antivirals
- Agreements
- Debiopharm Regains Full Rights To Alisporivir Programme
- Vical/AnGes Collaborate To Develop Therapy Against Ebola
- Product Updates
- Prevenar 13 Gains CHMP Positive Opinion For Vaccine-Type Pneumococcal Pneumonia In Adults
- AbbVie's Viekirax/Exviera Licensed For Use In UK For cHCV
- Payer Pressure Forces Gilead/AbbVie Drug Pricing Battle To Remain Heated
- Mylan Launches Lamivudine In US
- Health Canada Approves Novartis' Fluad Pediatric Flu Vaccine
- Gilead Likely To Weather The Indian Sofosbuvir Patent Rejection Storm
- R&D
- Chimerix Granted US Patent Allowance Covering Brincidofovir
- Waning Of Ebola Outbreak Could Hamper Vaccine Developments
- J&J Forms Ebola Vaccine Development Consortia; Secures Funding Corporate Activity
- Tekmira/OnCore Merge To Create Global HBV Company
- Merck Completes Tender Offer To Acquire Cubist
- Court Orders SIGA To Pay Tecovirimat Damages To PharmAthene
- Moderna Launches New Venture Valera For Infectious Diseases
- NovaBiotics Raises Funds Via Private Placement
